Patents by Inventor Michael Gerard Kelly

Michael Gerard Kelly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL CALCIUM MODULATORS
    Publication number: 20160207893
    Abstract: Disclosed are novel calcium modulators having formula I: or a pharmaceutically acceptable salt, and including deuterated forms thereof, wherein: Z1, Z2, Z3, Z4 Z5, R1, R1?, R2, R3, R3? R4, and R4?, are as defined throughout the specification; pharmaceutical compositions thereof; and methods of use thereof.
    Type: Application
    Filed: December 29, 2015
    Publication date: July 21, 2016
    Inventors: Michael Gerard Kelly, John Kincaid
  • Calcium receptor modulating agents
    Patent number: 8349831
    Abstract: The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: January 8, 2013
    Assignee: Amgen Inc.
    Inventors: Thomas S. Coulter, Adam James Davenport, Christopher H. Fotsch, Chiara Ghiron, Paul E. Harrington, Michael Gerard Kelly, Steve Fong Poon, Andrew Tasker, Ning Xi, Qing Ping Zeng
  • 1-ARYL-OR 1- ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
    Publication number: 20090239863
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: June 1, 2009
    Publication date: September 24, 2009
    Applicant: Wyeth
    Inventors: Ping Zhou, Michael Gerard Kelly
  • 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
    Patent number: 7557098
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: July 7, 2009
    Assignee: Wyeth
    Inventors: Michael Gerard Kelly, Derek Cecil Cole
  • 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
    Patent number: 7541370
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: September 6, 2007
    Date of Patent: June 2, 2009
    Assignee: Wyeth
    Inventors: Michael Gerard Kelly, Derek Cecil Cole
  • 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7541358
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: June 2, 2009
    Assignee: Wyeth
    Inventors: Ping Zhou, Michael Gerard Kelly
  • Calcium receptor modulating agents
    Publication number: 20080221101
    Abstract: The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.
    Type: Application
    Filed: October 25, 2007
    Publication date: September 11, 2008
    Applicant: Amgen Inc.
    Inventors: Thomas S. Coulter, Adam James Davenport, Christopher H. Fotsch, Chiara Ghiron, Paul E. Harrington, Michael Gerard Kelly, Steve Fong Poon, Andrew Tasker, Ning Xi, Qing Ping Zeng
  • 1-Aryl- or 1-Alkylsulfonyl-Heterocyclylbenzazoles As 5-Hydroxytryptamine-6 Ligands
    Publication number: 20080200455
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: August 20, 2007
    Publication date: August 21, 2008
    Applicant: Wyeth
    Inventors: Michael Gerard Kelly, Derek Cecil Cole
  • 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
    Patent number: 7282495
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: January 4, 2006
    Date of Patent: October 16, 2007
    Assignee: Wyeth
    Inventors: Michael Gerard Kelly, Derek Cecil Cole
  • 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7271180
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: September 18, 2007
    Assignee: Wyeth
    Inventors: Ping Zhou, Michael Gerard Kelly
  • 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
    Patent number: 7034029
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: April 25, 2006
    Assignee: Wyeth
    Inventors: Michael Gerard Kelly, Derek Cecil Cole
  • (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 6951881
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of a disorder relating to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: May 9, 2003
    Date of Patent: October 4, 2005
    Assignee: Wyeth
    Inventors: Derek Cecil Cole, Michael Gerard Kelly, Byron Abel Bravo, Yvette Latko Palmer
  • 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 6919354
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: October 29, 2003
    Date of Patent: July 19, 2005
    Assignee: Wyeth
    Inventors: Ping Zhou, Michael Gerard Kelly
  • Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 6906095
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of a disorder relating to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: May 9, 2003
    Date of Patent: June 14, 2005
    Assignee: Wyeth
    Inventors: Derek Cecil Cole, Michael Gerard Kelly, David Scott Nunn, Lynne Padilla Greenblatt
  • Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands
    Patent number: 6903112
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: October 23, 2003
    Date of Patent: June 7, 2005
    Assignee: Wyeth
    Inventors: Ping Zhou, Derek Cecil Cole, Michael Gerard Kelly, William Joseph Lennox
  • 1-Aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
    Publication number: 20040192749
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: January 16, 2004
    Publication date: September 30, 2004
    Applicant: Wyeth
    Inventors: Michael Gerard Kelly, Derek Cecil Cole
  • Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands
    Patent number: 6767912
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: July 27, 2004
    Assignee: Wyeth
    Inventors: Ping Zhou, Derek Cecil Cole, Michael Gerard Kelly, William Joseph Lennox
  • 1-Aryl-or 1-alkylsulfonyl-heterocyclybenzoles as 5-hydroxytryptamine-6 ligands
    Publication number: 20040132741
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: December 4, 2003
    Publication date: July 8, 2004
    Applicant: Wyeth
    Inventors: Michael Gerard Kelly, Derek Cecil Cole
  • Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands
    Publication number: 20040092526
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: October 23, 2003
    Publication date: May 13, 2004
    Applicant: Wyeth
    Inventors: Ping Zhou, Derek Cecil Cole, Michael Gerard Kelly, William Joseph Lennox
  • 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
    Publication number: 20040092564
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: October 28, 2003
    Publication date: May 13, 2004
    Applicant: Wyeth
    Inventors: Ping Zhou, Michael Gerard Kelly